Anti-Mouse TER-119 (Erythroid Cells) – Purified No Carrier Protein

Fetal liver cells from a C57BL/6 mouse

Liquid

Research Use Only

2 – 8° C Wet Ice

FC,
FA

TER-119 activity is directed against mouse Ter-119.

TER-119 recognizes a 52 kDa cell surface protein that strongly associates with glycophorin A on the erythrocyte membrane ¹ . The antigen is not present on a number of tested cell lines, including T cell, B cell, macrophage, mast cell, fibroblast, epithelial, and murine erythroleukemia cultured lines.

TER-119 is a mouse erythroid lineage-specific rat monoclonal antibody that reacts with 100% of mature erythrocytes and 80-90% of day 14 fetal liver cells, after which the percentage of TER-119⁺ fetal cells declines to 40-50% ². Additionally, TER-119 stains 20-25% of adult mouse bone marrow cells and 2-3% of spleen cells, but not thymocytes or lymph node cells.

TER-119 was produced in Wister rats immunized with BALB/c fetal liver cells ¹ . Spleen cells were fused with X63.Ag8.653 myeloma cells to produce a hybridoma clone reactive against fetal liver cells. TER-119 recognizes a 7,9 di-O-acetyl sialic acid glyco-epitope ³ . Additionally, the epitope is sensitive to hemagglutinin esterase derived from bovine coronavirus (Mebus strain) but not influenza C.

TER-119 is highly specific for erythroid cells, from early proerythroblasts to mature erythrocytes. TER-119 antigen is expressed on normal erythroid cells, but not erythroleukemia cells, even when induced with dimethylsulfoxide. TER-119 is not thought to interact with pluripotent hematopoietic stem cells in adult bone marrow.

1 Kina T, Ikuta K, Takayama E, et al. Br J Haematol. 109(2):280-287. 2000.
2 Ikuta K, Kina T, MacNeil I, et al. Cell. 62(5):863-874. 1990.
3 Mahajan VS, Alsufyani F, Mattoo H, et al. Glycobiology. 29(3):222-228. 2019.
4 Otani T, Nakamura S, Inoue T, et al. Exp Hematol. 32(7):607-613. 2004.
5 Brendt P, Rehfeld I, Kamphausen A, et al. Anaesthesia. 67(5):493-500. 2012.
6 Kimball A, Schaller M, Joshi A, et al. Arterioscler Thromb Vasc Biol. 38(5):1102-1114. 2018.
7 Juban G, Sakakini N, Chagraoui H, et al. Haematologica. 106(4):1106-1119. 2021.
8 Perik-Zavodskaia O, Perik-Zavodskii R, Nazarov K, et al. Int J Mol Sci. 24(21):15752. 2023.
9 Mqadmi A, Abramowitz S, Zheng X, et al. Immunohematology. 22(1):11-4. 2006.
10 Kumon K, Afify SM, Hassan G, et al. Sci Rep. 11(1):23977. 2021.